Covered
GRND · Grindr Inc.
Updated ·
Against its published line
Above its line on the last close.
How to read this
The red mark is the published kill line — the price that would prove the thesis wrong. The dot is where the name closed on 28 October 2026; a dot left of the mark has closed through its line.
Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row reads well clear, with a hollow dot to show the figure is off the drawn scale. Rows run tightest first.
Kill line
A daily close below $12.50, under the 28 October 2026 close of $12.97 and the lowest level in the weeks since the PurposeMed announcement. A cut to the roughly $540 million 2026 revenue guidance, or Q3 average revenue per paying user below $26.51, would also break the case.
Not a pickResearch coverage at low conviction. A medium-or-higher call would open a pick on the scoreboard.
Catalyst (1 day ago)
How picks are graded →The thesis
Grindr's paid-subscription business is growing, but the 30 September 2026 agreement to buy telehealth company PurposeMed for $250 million moved the story away from the premium-tier pivot, and the shares have fallen to $12.97. The Q3 report after the market close on 5 November 2026, which includes the first 2027 outlook, settles whether the core business still supports the August guidance and what the combined company costs to run.
The shares closed at $12.97 on 28 October 2026, down from $15.10 on 15 October 2026 and 27.7% below the 52-week high of $17.94. They are 25.2% lower over three months. The 14-day relative strength index (a 0–100 gauge of recent buying versus selling) reads 25.1, against 44.3 on 15 October 2026. The close is below the $13.43 close of 2 October 2026 that followed the deal announcement.
The narrative is maturing and has turned heavier: the 6 August 2026 guidance raise is well known, the deal dominated attention from 30 September 2026, and the sector bounce around the 12 October 2026 Bumble take-private reports has reversed in Grindr's shares. A search of company news and filings through 28 October 2026 found no Grindr-specific item that explains the drop. The only company release in the period is the 22 October 2026 notice that the Q3 call is set for 5 November 2026.
Bullish and bearish views on Grindr Inc.
The bull case on Grindr Inc. (GRND), in brief: Subscription growth is reported, not forecast. The bear case: The deal changes what the company is.
Bull case
- Subscription growth is reported, not forecast. Q2 2026 revenue was $138.1 million, up 33% year over year, and full-year revenue guidance rose to about $540 million on 6 August 2026 (Q2 shareholder letter). Paying users averaged about 1.4 million, up 16%, and average revenue per paying user was $26.51, up 12%.
- The acquired business is profitable. Grindr said on 30 September 2026 that Freddie expects 2026 revenue above $80 million and adjusted EBITDA above $10 million, with over 25,000 active patients. Grindr expects an immaterial effect on 2026 results.
- Analyst targets sit well above the price. Goldman Sachs maintained a Buy with a $19 target on 1 October 2026, and Raymond James raised its target to $22 on 7 August 2026. Morgan Stanley's target moved from $18 to $20 on 8 September 2026, per StockAnalysis.com. The S&P Global consensus target is $20.80 across five analysts.
- Take-private activity in the sector. Bumble was reported on 12 October 2026 to be in advanced talks to go private at about a $1 billion valuation, and Reuters later reported an agreed deal valued at $1.3 billion. The price paid for a weaker dating-app peer has not carried over to Grindr's shares.
Bear case
- The deal changes what the company is. Grindr moves from a social app with a premium tier to a telehealth operator for HIV-prevention (PrEP) care. The 8-K gives no financing source for the $190 million cash portion, and the $60 million stock portion adds shares.
- EDGE remains unmeasured. Management described commercialization of the EDGE tier on 10 September 2026 as starting later this year or early next year, with no US price point. No reported revenue from the tier exists yet.
- Controlling-holder supply is possible. A Schedule 13D amendment signed 18 June 2026 records a plan to sell up to 6,000,000 shares, expected to run from 16 September 2026 to 15 March 2027. The group was reported at 53.7% of shares outstanding. No new sale filing is listed after 16 September 2026.
- Earnout adds a later cash call. Up to $70 million more in cash is payable in 2028 if Freddie meets 2027 targets (8-K, 30 September 2026).
- Store dependence persists. App revenue was $112.9 million of the $138.1 million Q2 total, billed largely through Apple and Google.
- The prior note's fade risk has played out. The 16 October 2026 note named a daily close below the $14.50 weekly level, with no company news in between, as the sign that the rise was sector-driven. The shares closed at $12.97 on 28 October 2026 with no company-specific news found.
Price setup
The last adjusted close is $12.97 (28 October 2026). That is 27.7% below the 52-week high of $17.94 and about $2.71 below the $15.68 close that preceded the PurposeMed announcement. The $13.43 close of 2 October 2026, which marked the post-announcement low in the previous note, no longer holds.
The relative strength index of 25.1 is in the range usually read as heavily oversold. Interest has not turned: the decline of $2.13 from $15.10 on 15 October 2026 took place over eight sessions without a company filing explaining it.
Crowding evidence points to supply and event risk rather than heavy buying. The Q3 report is seven calendar days away. A scheduled 10b5-1 selling plan for the controlling holder is in its window, and the Chief Legal Officer sells under his own plan. Retail attention is not measured in available data.
Catalysts, next 30 days
- Q4 2026, by 31 December 2026: expected close of the PurposeMed acquisition, subject to customary conditions.
- 31 December 2026: first £13 million instalment of the UK group-action settlement falls due.
Elapsed catalysts
- 5 November 2026, after the market close: Q3 2026 shareholder letter and call at 5:00 p.m. Eastern Time (company release, 22 October 2026). It tests the roughly $540 million revenue guidance, the $26.51 average revenue per paying user, and the first 2027 outlook with PurposeMed. (passed 1d ago)
What would change the view
The case breaks if the Q3 report cuts the roughly $540 million revenue guidance or shows average revenue per paying user below the $26.51 reported for Q2. A 2027 outlook that carries heavy telehealth investment without a matching core subscription forecast would also weaken it. Disclosure of EDGE delays, or a Schedule 13D amendment or Form 4 showing controlling-holder sales, would add to the bear case.
On price, a daily close below $12.50 ends the thesis. A report that holds guidance, keeps revenue per paying user at or above $26.51 and sizes the telehealth spend would show the core still carries the story.
What it trades with
Grindr trades with dating and social-app peers. Bumble's 12 October 2026 take-private reports lifted both names, and the move did not last in Grindr's shares. App-store fee policy at Apple and Google is a shared exposure for all subscription apps. The 53.7% controlling holder group makes block-sale supply a company-specific factor that peers do not share.
Notes
- Majority holder group (San Vicente entities) was reported at 53.7% of shares outstanding, so free float is constrained and block-sale supply is a standing feature.
- A Schedule 13D amendment signed 18 June 2026 records a Rule 10b5-1 plan (a pre-scheduled selling plan) for up to 6,000,000 shares, expected to run from 16 September 2026 to 15 March 2027.
- Chief Legal Officer Zachary Katz sells under a 10b5-1 plan adopted 18 March 2026; his Form 4 filings are scheduled sales.
- App revenue was $112.9M of $138.1M total in Q2 2026 and is billed largely through Apple and Google, so store fee or policy changes hit revenue directly.
- Screener target pages mix vintages: a $26 Raymond James figure dates to May 2025, not the 7 August 2026 revision to $22.